Cyclacel Pharmaceuticals (NASDAQ:CYCC) Posts Quarterly Earnings Results, Beats Estimates By $0.36 EPS

Cyclacel Pharmaceuticals (NASDAQ:CYCC) announced its quarterly earnings data on Tuesday. The biotechnology company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.36, Zacks reports. The company had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.01 million. Cyclacel Pharmaceuticals had a negative net margin of 18,150.00% and a negative return on equity of 1,901.11%.

Cyclacel Pharmaceuticals Trading Down 12.6 %

NASDAQ:CYCC opened at $0.39 on Friday. Cyclacel Pharmaceuticals has a 12 month low of $0.37 and a 12 month high of $6.00. The firm has a fifty day simple moving average of $0.87 and a 200-day simple moving average of $1.43.

Wall Street Analyst Weigh In

CYCC has been the subject of a number of recent research reports. StockNews.com initiated coverage on Cyclacel Pharmaceuticals in a research note on Friday. They set a “sell” rating for the company. Roth Capital downgraded shares of Cyclacel Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 23rd.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.